Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 8/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | GAK | O14976 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7602494 | 0.92 | PDGFRB (0.48) | PDGFRBPDGFRAESR2CA1CA2 | |
| SCHEMBL15108960 | 0.88 | PDGFRB (0.44) | PDGFRBPDGFRAESR2CA1CA2 | |
| SCHEMBL15161581 | 0.82 | PDGFRB (0.41) | PDGFRBPDGFRAESR2CA1CA2 | |
| SCHEMBL26549500 | 0.81 | CA12 (0.57) | PDGFRBPDGFRACA1CA2CA12 | |
| SCHEMBL7601977 | 0.79 | NPC1 (0.52) | CA1CA2HSD11B1 | |
| SCHEMBL15851457 | 0.78 | HSD11B1 (0.44) | CA1CA2CA12CA9HSD11B1 | |
| SCHEMBL28294470 | 0.78 | PDGFRB (0.47) | PDGFRBPDGFRACA1CA2CA12 | |
| SCHEMBL28245204 | 0.78 | CA1 (0.44) | PDGFRBPDGFRAMAOBCA1CA2 | |
| SCHEMBL16811754 | 0.75 | HSD11B1 (0.48) | CA1CA2CA9HSD11B1 | |
| SCHEMBL31243801 | 0.75 | HSD11B1 (0.48) | CA1CA2CA9HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-8921369-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | PDGFRB 330/4885PDGFRA 657/4885MAOB 4087/4885 |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | PDGFRB 338/4885PDGFRA 677/4885MAOB 4055/4885 |
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | PDGFRB 338/4885PDGFRA 677/4885MAOB 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.